Introduction to the Scientific Program.

Accreditation provides an important framework for confidence in laboratory competence and the reliability of testing. Explore what accreditation demonstrates, how its scope relates to particular test methods, and why internationally recognised results still need to be interpreted in their regulatory and product-specific context. 

ISO standards help create common approaches to cosmetic microbiology, yet applying a standard does not eliminate the need for scientific judgment. Examine how relevant microbiological standards are developed and used, where methodological consistency supports comparable results, and which product or market considerations still affect the assessment of microbiological quality and safety.

How should microbiological test results influence real product-safety decisions? Examine microbiological quality, preservative efficacy, contamination control and product-specific risk, including the difference between meeting a numerical criterion and understanding its significance. The session will connect laboratory findings with the scientific justification needed for assessment, investigation and follow-up.

When does a microbiological finding require additional testing, investigation, reformulation or another compliance action? Using practical decision questions around challenge tests, deviations and borderline results, this forum will explore how laboratories, accreditation experts, safety assessors and Responsible Persons interpret uncertainty. The objective is to clarify what evidence is needed before a defensible decision can be made.

Article 17 of Regulation (EC) No 1223/2009 addresses the non-intended presence of small quantities of prohibited substances under specific conditions. Examine how this provision is interpreted in practice, the importance of technical unavoidability and good manufacturing practice, and the evidence needed to assess whether trace findings are compatible with product safety and compliance.

Analytical results can reveal impurities, contaminants or restricted substances, but a detected value does not automatically determine the regulatory outcome. Explore method selection, sensitivity, specifications and trace-level analysis, and how laboratories and regulatory teams should assess results against applicable limits, product context and scientific uncertainty before deciding on next steps.

The Responsible Person must bring together supplier information, laboratory reports and the safety assessment into a defensible compliance position. This session will examine how RPs decide which tests are necessary, evaluate unexpected or incomplete results, request clarification from laboratories and document the rationale for action or no further action. The emphasis is on practical ownership of the final compliance decision.

How much testing is enough—and when is more testing unlikely to improve the decision? RPs, laboratories, assessors and industry representatives will explore risk-based testing strategies, the use of supplier evidence, proportionality and scientific justification. The discussion will examine how to defend necessary testing, identify avoidable duplication and respond when evidence remains incomplete.

Testing requirements affect more than finished products: they also shape ingredient specifications, supplier documentation, analytical controls and the exchange of safety information along the value chain. Examine how changing evidence expectations influence ingredient suppliers and manufacturers, and where earlier coordination can prevent duplication, delays or gaps in the finished-product safety assessment.

How do testing expectations affect decisions long before a cosmetic product reaches the market? Through a manufacturer’s perspective, explore how evidence requirements influence ingredient selection, formulation development, stability and quality planning, timelines and launch readiness. The session will connect regulatory testing obligations with everyday R&D choices and the trade-offs involved in bringing a compliant product to market.

Smaller cosmetics manufacturers face many of the same safety and compliance obligations as larger companies, but often with fewer technical resources and tighter budgets. Explore which testing and documentation requirements create the greatest operational pressure, where access to expert support and supplier data matters, and how SMEs can adopt proportionate, risk-based approaches without compromising safety.

The summit concludes by bringing together authorities, Responsible Persons, laboratories, safety assessors and industry representatives to examine how cooperation could work better in practice. Building on both days, the forum will identify recurring friction points in evidence generation, method acceptance, interpretation and communication—and seek concrete priorities for clearer expectations and more effective collaboration.